January 2026
Neuroplasticity
What January 2026's 11 new studies found, synthesized from the papers below. All Neuroplasticity research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.
Research published in January 2026 consistently finds that serotonergic psychedelics (psilocybin, DMT) promote neuroplasticity—including synaptogenesis, neurogenesis, and synaptic remodeling—which is linked to rapid and sustained antidepressant effects. Evidence comes from preclinical models, human neuroimaging, and clinical trials, but most studies are reviews or small-sample experiments, and durability beyond one year remains unstudied.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects 2026 | narrative review | Supports | Psilocybin induces structural synaptic remodeling in frontal cortex and hippocampal plasticity, linked to sustained antidepressant effects up to six months. | |
| Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model. 2026 | preclinical animal study | Supports | Single-dose DMT reversed anhedonia and cognitive deficits via increased adult-born granule cell integration and reduced ectopic cells, outperforming chronic fluoxetine. | |
| The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence 2026 | narrative review | Supports | Psilocybin enhances synaptogenesis and functional reorganization, with large effect sizes and durable benefits lasting up to one year. | |
| Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment. 2026 | narrative review | Supports | Classic psychedelics promote neurogenesis and behavioral responses via molecular targets associated with neuroplasticity. | |
| Zalsupindole: A Non-Hallucinogenic Psychoplastogen Advancing Psychedelic-Inspired Therapeutics. 2026 | narrative review | Supports | Zalsupindole, a non-hallucinogenic psychoplastogen, shows neuroplasticity-promoting effects in peer-reviewed in vitro and in vivo studies. | |
| [Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges]. 2026 | narrative review | Supports | Psychedelics rapidly promote neurotrophic factor release and enhance neuroplasticity, creating a 'neuroplastic window' for psychotherapy, though mechanisms are debated. | |
| Modeling Antidepressant-Induced Manic Switch and Longitudinal Relapse: A Unified Pruning Framework Highlights Glutamatergics' Disease-Modifying Potential 2026 | computational modeling study | Supports | Ketamine-like simulated synaptic regrowth restored performance and showed disease-modifying potential, contrasting with SSRI and neurosteroid models. | |
| An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice 2026 | preclinical animal study | Supports | Psilocybin dose-dependently occupied 5-HT2A receptors and shifted microtubule dynamics toward plasticity, with increased synaptic markers in prefrontal cortex. | |
| Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: a case report. 2026 | case report | 1 | Supports | High-dose psilocybin-containing mushrooms led to transient multidomain functional improvement, suggesting plasticity-related mechanisms in advanced dementia. |
| Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity 2026 | preclinical in vitro study | Supports | LSD, psilocin, and DMT decreased synaptic vesicle fusion and modulated presynaptic mechanisms, indicating effects on synaptic function and plasticity. | |
| The entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") disrupts helping behaviour while reinforcing electrophysiological indicators of potentially associated synaptic plasticity in male Sprague-Dawley rats. 2026 | preclinical animal study | Mixed | MDMA suppressed helping behavior at high doses but reinforced electrophysiological indicators of synaptic plasticity, showing dissociation between behavior and plasticity. |
Psilocybin induces structural synaptic remodeling in frontal cortex and hippocampal plasticity, linked to sustained antidepressant effects up to six months.
narrative review
Single-dose DMT reversed anhedonia and cognitive deficits via increased adult-born granule cell integration and reduced ectopic cells, outperforming chronic fluoxetine.
preclinical animal study
Psilocybin enhances synaptogenesis and functional reorganization, with large effect sizes and durable benefits lasting up to one year.
narrative review
Classic psychedelics promote neurogenesis and behavioral responses via molecular targets associated with neuroplasticity.
narrative review
Zalsupindole, a non-hallucinogenic psychoplastogen, shows neuroplasticity-promoting effects in peer-reviewed in vitro and in vivo studies.
narrative review
Psychedelics rapidly promote neurotrophic factor release and enhance neuroplasticity, creating a 'neuroplastic window' for psychotherapy, though mechanisms are debated.
narrative review
Ketamine-like simulated synaptic regrowth restored performance and showed disease-modifying potential, contrasting with SSRI and neurosteroid models.
computational modeling study
Psilocybin dose-dependently occupied 5-HT2A receptors and shifted microtubule dynamics toward plasticity, with increased synaptic markers in prefrontal cortex.
preclinical animal study
High-dose psilocybin-containing mushrooms led to transient multidomain functional improvement, suggesting plasticity-related mechanisms in advanced dementia.
case report Sample size: 1
LSD, psilocin, and DMT decreased synaptic vesicle fusion and modulated presynaptic mechanisms, indicating effects on synaptic function and plasticity.
preclinical in vitro study
MDMA suppressed helping behavior at high doses but reinforced electrophysiological indicators of synaptic plasticity, showing dissociation between behavior and plasticity.
preclinical animal study
Points of agreement
- Serotonergic psychedelics (psilocybin, DMT, LSD) consistently promote neuroplasticity markers such as synaptogenesis, neurogenesis, and synaptic remodeling.
- Neuroplasticity is linked to rapid and sustained antidepressant effects in both preclinical models and clinical settings.
- The 5-HT2A receptor is a key mediator of these plasticity effects.
Conflicts
- One study (article_id 28508) found that MDMA suppressed helping behavior while still inducing plasticity markers, suggesting a dissociation between behavioral effects and neuroplasticity.
- Debate exists over whether plasticity is primarily 5-HT2A-dependent or involves TrkB neurotrophic pathways (article_id 19469).
Gaps
- Durability of neuroplastic changes beyond one year is not studied.
- Most human evidence comes from reviews or small trials; large-scale RCTs with neuroplasticity endpoints are lacking.
- The role of the psychedelic experience versus direct pharmacological effects on plasticity remains unclear.
- Effects in diverse populations (e.g., different ages, comorbidities) are understudied.
- Long-term safety and risk of manic switch in bipolar populations are not addressed.